Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q4 EPS of ($0.51), $0.06 worse than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.